News

Nature2d
Imatinib buys time for brain after stroke - Nature Medicine
News & Views Published: July 2008 Imatinib buys time for brain after stroke Peter Rieckmann Nature Medicine 14, 712–713 (2008) Cite this article ...
ascopubs.org8d
Combination signal transduction inhibition: a phase I/II trial of the oral mTOR-inhibitor everolimus (E, RAD001) and imatinib mesylate (IM) in patients (pts) with ...
Background: Primary resistance to IM in advanced GIST pts occurs rarely (<15%), but eventually pts may develop secondary resistance, possibly due to other mutations of KIT, genomic amplification of ...
Nature8d
Imatinib mesylate suppresses cytokine synthesis by activated CD4 T cells of patients with chronic myelogenous leukemia - Nature
Although imatinib mesylate (IM) is highly effective at inducing complete cytogenetic remission in patients with chronic myelogenous leukemia (CML), it is known to suppress T-cell proliferation in ...
C&EN23d
Application of Quality by Design Principles for the Definition of a Robust Crystallization Process for Casopitant Mesylate
GlaxoSmithKline (GSK) has identified casopitant as a potent NK1 antagonist. It was selected for its potential activities on a number of therapeutic targets such as inflammatory bowel disease, ...
thorax.bmj26d
Preliminary data suggestive of a novel translational approach to mesothelioma treatment: imatinib mesylate with gemcitabine or pemetrexed - Thorax
Background: Malignant mesothelioma is a cancer which is refractory to current treatments. Imatinib mesylate is a selective inhibitor of tyrosine kinases such as bcr-abl, c-Kit, c-Fms and platelet ...